ERBB2 and breast carcinoma: To date, HER2+ breast cancer patients are defined as IHC score 3 + or score 2+ with a positive ISH, and subsequently qualified for anti-HER2 targeted therapy (Pondé et al., 2018; Wolff et al., 2018).